Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) - Full Text View

Sponsor:	CSL Behring
Information provided by:	CSL Behring
ClinicalTrials.gov Identifier:	NCT00322556

Purpose

The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.

Condition	Intervention	Phase
Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency	Drug: Immunoglobulins Intravenous (Human)	Phase III

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)

Resource links provided by NLM:

Genetics Home Reference related topics: aceruloplasminemia common variable immune deficiency complement factor I deficiency X-linked agammaglobulinemia X-linked hyper IgM syndrome

Drug Information available for: Immunoglobulins Globulin, Immune

U.S. FDA Resources

Further study details as provided by CSL Behring:

Primary Outcome Measures:

Safety endpoints: The proportion of infusions temporally (during infusion and within 48 hours after the end of infusion) associated with one or more AEs [ Time Frame: Will be recoreded as they occur during study ] [ Designated as safety issue: Yes ]
Influence of infusion rate on adverse events [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Rate, severity and relationship of all AEs [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Vital sign changes during each infusion [ Time Frame: Every 3 or 4 weeks depending on dosing schedule ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Efficacy endpoints: Rate of acute serious bacterial infections; [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Number of days out of work / school / kindergarten / day care due to underlying PID [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Number of days of hospitalization [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Rate of any infections [ Time Frame: Will be recorded as they occur during study ] [ Designated as safety issue: Yes ]
Trough levels of total IgG serum concentrations [ Time Frame: Every three or four weeks depending on dosing schedule prior to infusion ] [ Designated as safety issue: No ]

Enrollment:	44
Study Start Date:	November 2005
Study Completion Date:	April 2008
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Intervention Details:

Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw

Eligibility

Ages Eligible for Study:	4 Years to 71 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Key Inclusion Criteria:

Patients with CVID (Common Variable Immunodeficiency) or XLA (X-linked agammaglobulinemia) who have participated in the Phase III clinical study with intravenous IgPro10 (study number ZLB03_002CR) at 3- or 4- weekly intervals for 12 months
Written informed consent

Key Exclusion Criteria:

Diagnosis of epilepsia
Insulin dependent diabetes
Administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs
History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00322556

Locations

United States, California
Contact CSL Behring for facility details
Los Angeles, California, United States, 90027
United States, Colorado
Contact CSL Behring for facility details
Centennial, Colorado, United States, 80112
United States, Florida
Contact CSL Behring for facility details
North Palm Beach, Florida, United States, 33408
Contact CSL Behring for facility details
St. Petersburg, Florida, United States, 33701
United States, Indiana
Contact CSL Behring for facility details
Indianapolis, Indiana, United States, 46202
United States, Iowa
Contact CSL Behring for facility details
Iowa City, Iowa, United States, 52242
United States, Minnesota
Contact CSL Behring for facility details
Rochester, Minnesota, United States, 55905
United States, Missouri
Contact CSL Behring for facility details
St. Louis, Missouri, United States, 63104-1095
United States, Texas
Contact CSL Behring for facility details
Dallas, Texas, United States, 75230

Sponsors and Collaborators

CSL Behring

More Information

Additional Information:

Click here to request more information about this study This link exits the ClinicalTrials.gov site

Publications:

Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen(R), at Different Infusion Rates. J Clin Immunol. 2010 Mar 10; [Epub ahead of print]

Responsible Party:	Global Head Clinical Research & Development, CSL Behring
ClinicalTrials.gov Identifier:	NCT00322556 History of Changes
Other Study ID Numbers:	ZLB05_006CR
Study First Received:	May 5, 2006
Last Updated:	February 10, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by CSL Behring:

Immunoglobulin Intravenous
Agammaglobulinemia
Hypogammaglobulinemia

Common variable immunodeficiency
Immunoglobulin G
Children

Additional relevant MeSH terms:

Agammaglobulinemia
Common Variable Immunodeficiency
Immunologic Deficiency Syndromes
IgG Deficiency
Blood Protein Disorders
Hematologic Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Immune System Diseases

Dysgammaglobulinemia
Immunoglobulins
Antibodies
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012